SCHEMBL30332210

SCHEMBL30332210

CC(C)(C)n1cc(-c2ccccc2C#N)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 4/20 0.48
▸ KDM5A P29375 1/20 0.44
▸ KDM5C P41229 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44
▸ KDM5B Q9UGL1 1/20 0.44
▸ ESR2 Q92731 1/20 0.42
▸ GABRG2 P18507 6/20 0.41
▸ GABRB3 P28472 6/20 0.41
▸ GABRA5 P31644 4/20 0.41
▸ GABRA3 P34903 4/20 0.41
▸ BRD4 O60885 2/20 0.41
▸ CREBBP Q92793 2/20 0.41
▸ EP300 Q09472 1/20 0.41
▸ GABRA1 P14867 5/20 0.41
▸ GABRA2 P47869 4/20 0.41
▸ TRPA1 O75762 1/20 0.40
▸ NR3C1 P04150 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ PTPN5 P54829 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23753798 0.80 CNR1 (0.52) PDK2ESR2GABRG2GABRB3GABRA5
SCHEMBL30331886 0.78 CNR2 (0.45) PDK2KDM5AKDM5CKDM4CKDM5B
SCHEMBL30332122 0.73 PDK2 (0.48) PDK2BRD4CREBBPEP300
SCHEMBL30332345 0.72 PDK2 (0.49) PDK2ESR2GABRG2GABRB3GABRA5
SCHEMBL30932023 0.71 KDM5A (0.39) PDK2KDM5AKDM5CKDM4CKDM5B
SCHEMBL31130940 0.71 RET (0.41) —
SCHEMBL5219316 0.70 GRM5 (0.61) ESR2GABRG2GABRB3GABRA5GABRA3
SCHEMBL30796163 0.70 GRM5 (0.61) ESR2GABRG2GABRB3GABRA5GABRA3
SCHEMBL14231513 0.68 ESR2 (0.56) PDK2ESR2GABRG2GABRB3GABRA5
SCHEMBL18045672 0.68 GRM4 (0.60) PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023046128-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2023-03-30 — — WO disclosed
Send feedback